Studies performed in recent years suggest that selected connexins—i.e., Cx43, Cx26 and Cx32—could serve as biomarkers in prognosing the course of cancers or exploited for therapeutic strategies in cancer management [90]. This evidence concerns the gene GJB2 and cancer.